Obicetrapib Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg; 10 mg + ezetimibe 10 mg

Reference Brands: Ubeslo, Evlarco (with ezetimibe)

Category: Heart Disorder

Obicetrapib is a once-daily CETP inhibitor that lowers LDL cholesterol. The European Commission approved it in September 2026 as Ubeslo, and with ezetimibe as Evlarco. It is not yet approved in the US. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Obicetrapib blocks cholesteryl ester transfer protein (CETP), which moves cholesterol from HDL particles into LDL and other particles. Earlier CETP inhibitors raised HDL but did little for LDL and were dropped. Obicetrapib is more potent and lowers LDL cholesterol substantially as well as apolipoprotein B and lipoprotein(a), at a dose of 10 mg once a day.

The European Commission approved obicetrapib on 21 September 2026, its first approval anywhere, for adults with primary hypercholesterolaemia (familial and non-familial) or mixed dyslipidaemia whose LDL is not controlled. It comes alone as Ubeslo and as a fixed-dose tablet with ezetimibe 10 mg as Evlarco, to be used with a statin or where a statin is not tolerated. NewAmsterdam Pharma developed it; Menarini markets it in Europe. It is not yet approved in the US.

Sourcing and licensing notes. Obicetrapib is patented and there is no generic. European launches are only starting, so supply outside the EU depends on import permits and the originator's release plans. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule and its ezetimibe combination ahead of patent expiry.